VIKING THERAPEUTICS INC (VKTX) Stock Fundamental Analysis

NASDAQ:VKTX • US92686J1060

34.02 USD
+2.99 (+9.64%)
Last: Feb 23, 2026, 12:39 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, VKTX scores 3 out of 10 in our fundamental rating. VKTX was compared to 521 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VKTX as it has an excellent financial health rating, but there are worries on the profitability. VKTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year VKTX has reported negative net income.
  • In the past year VKTX has reported a negative cash flow from operations.
  • VKTX had negative earnings in each of the past 5 years.
  • VKTX had a negative operating cash flow in each of the past 5 years.
VKTX Yearly Net Income VS EBIT VS OCF VS FCFVKTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M

1.2 Ratios

  • VKTX has a Return On Assets (-50.25%) which is comparable to the rest of the industry.
  • VKTX has a better Return On Equity (-56.28%) than 63.92% of its industry peers.
Industry RankSector Rank
ROA -50.25%
ROE -56.28%
ROIC N/A
ROA(3y)-28.55%
ROA(5y)-30.53%
ROE(3y)-31.14%
ROE(5y)-33.61%
ROIC(3y)N/A
ROIC(5y)N/A
VKTX Yearly ROA, ROE, ROICVKTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • VKTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VKTX Yearly Profit, Operating, Gross MarginsVKTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • The number of shares outstanding for VKTX has been increased compared to 1 year ago.
  • Compared to 5 years ago, VKTX has more shares outstanding
  • There is no outstanding debt for VKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VKTX Yearly Shares OutstandingVKTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
VKTX Yearly Total Debt VS Total AssetsVKTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 25.05 indicates that VKTX is not in any danger for bankruptcy at the moment.
  • VKTX has a Altman-Z score of 25.05. This is amongst the best in the industry. VKTX outperforms 90.98% of its industry peers.
  • There is no outstanding debt for VKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 25.05
ROIC/WACCN/A
WACCN/A
VKTX Yearly LT Debt VS Equity VS FCFVKTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 9.33 indicates that VKTX has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 9.33, VKTX belongs to the top of the industry, outperforming 80.04% of the companies in the same industry.
  • A Quick Ratio of 9.33 indicates that VKTX has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 9.33, VKTX belongs to the top of the industry, outperforming 80.04% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.33
Quick Ratio 9.33
VKTX Yearly Current Assets VS Current LiabilitesVKTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • VKTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -218.00%.
EPS 1Y (TTM)-218%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-331.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 27.67% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-19.4%
EPS Next 2Y-14.49%
EPS Next 3Y-6.42%
EPS Next 5Y27.67%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VKTX Yearly Revenue VS EstimatesVKTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2028 2029 2030 2031 2032 2033 1B 2B 3B 4B 5B
VKTX Yearly EPS VS EstimatesVKTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • VKTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year VKTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VKTX Price Earnings VS Forward Price EarningsVKTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VKTX Per share dataVKTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • VKTX's earnings are expected to decrease with -6.42% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.49%
EPS Next 3Y-6.42%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for VKTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VIKING THERAPEUTICS INC

NASDAQ:VKTX (2/23/2026, 12:39:53 PM)

34.02

+2.99 (+9.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-11
Earnings (Next)04-21
Inst Owners66%
Inst Owner Change-1.56%
Ins Owners2.17%
Ins Owner Change1.52%
Market Cap3.85B
Revenue(TTM)N/A
Net Income(TTM)-359.64M
Analysts85.83
Price Target95.94 (182.01%)
Short Float %23.61%
Short Ratio8.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-34.26%
Min EPS beat(2)-51.32%
Max EPS beat(2)-17.21%
EPS beat(4)0
Avg EPS beat(4)-29.95%
Min EPS beat(4)-51.32%
Max EPS beat(4)-17.21%
EPS beat(8)3
Avg EPS beat(8)-10.43%
EPS beat(12)5
Avg EPS beat(12)-6.84%
EPS beat(16)6
Avg EPS beat(16)-5.84%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.87%
EPS NQ rev (1m)-19.22%
EPS NQ rev (3m)-18.12%
EPS NY rev (1m)0.02%
EPS NY rev (3m)-2.79%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-12.49%
Revenue NY rev (3m)-18.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.02
P/tB 6.02
EV/EBITDA N/A
EPS(TTM)-3.18
EYN/A
EPS(NY)-3.8
Fwd EYN/A
FCF(TTM)-2.47
FCFYN/A
OCF(TTM)-2.47
OCFYN/A
SpS0
BVpS5.65
TBVpS5.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.25%
ROE -56.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.55%
ROA(5y)-30.53%
ROE(3y)-31.14%
ROE(5y)-33.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.33
Quick Ratio 9.33
Altman-Z 25.05
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-218%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-331.25%
EPS Next Y-19.4%
EPS Next 2Y-14.49%
EPS Next 3Y-6.42%
EPS Next 5Y27.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-160.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-25.5%
EBIT Next 3Y-13.64%
EBIT Next 5Y18.49%
FCF growth 1Y-217.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-217.44%
OCF growth 3YN/A
OCF growth 5YN/A

VIKING THERAPEUTICS INC / VKTX FAQ

What is the ChartMill fundamental rating of VIKING THERAPEUTICS INC (VKTX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to VKTX.


What is the valuation status of VIKING THERAPEUTICS INC (VKTX) stock?

ChartMill assigns a valuation rating of 0 / 10 to VIKING THERAPEUTICS INC (VKTX). This can be considered as Overvalued.


What is the profitability of VKTX stock?

VIKING THERAPEUTICS INC (VKTX) has a profitability rating of 1 / 10.


What is the expected EPS growth for VIKING THERAPEUTICS INC (VKTX) stock?

The Earnings per Share (EPS) of VIKING THERAPEUTICS INC (VKTX) is expected to decline by -19.4% in the next year.